Integrative analysis of miRNA-mRNA network in high altitude retinopathy by bioinformatics analysis.
Bioinformatics analysis
Differentially expressed genes
High-altitude retinopathy
MiRNA-mRNA network
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
29 01 2021
29 01 2021
Historique:
received:
19
03
2020
revised:
27
11
2020
accepted:
24
12
2020
pubmed:
5
1
2021
medline:
15
12
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
High-altitude retinopathy (HAR) is an ocular manifestation of acute oxygen deficiency at high altitudes. Although the pathophysiology of HAR has been revealed by many studies in recent years, the molecular mechanism is not yet clear. Our study aimed to systematically identify the genes and microRNA (miRNA) and explore the potential biomarkers associated with HAR by integrated bioinformatics analysis. The mRNA and miRNA expression profiles were obtained from the Gene Expression Omnibus database. We performed Gene Ontology functional annotations and Kyoto Encyclopedia of Genes and Genomes pathway analysis. Potential target gene analysis and miRNA-mRNA network analysis were also conducted. Quantitative RT-PCR (qRT-PCR) was used to validate the results of the bioinformatics analysis. Through a series of bioinformatics analyses and experiments, we selected 16 differentially expressed miRNAs (DE-miRNAs) and 157 differentially expressed genes related to acute mountain sickness (AMS) and constructed a miRNA-mRNA network containing 240 relationship pairs. The hub genes were filtered from the protein-protein interaction network: IL7R, FOS, IL10, FCGR2A, DDX3X, CDK1, BCL11B and HNRNPH1, which were all down-regulated in the AMS group. Then, nine up-regulated DE-miRNAs and eight hub genes were verified by qRT-PCR in our hypoxia-induced HAR cell model. The expression of miR-3177-3p, miR-369-3p, miR-603, miR-495, miR-4791, miR-424-5p, FOS, IL10 and IL7R was consistent with our bioinformatics results. In conclusion, FOS, IL10, IL-7R and 7 DE-miRNAs may participate in the development of HAR. Our findings will contribute to the identification of biomarkers and promote the effective prevention and treatment of HAR in the future.
Identifiants
pubmed: 33393628
pii: 227459
doi: 10.1042/BSR20200776
pmc: PMC7809558
pii:
doi:
Substances chimiques
MicroRNAs
0
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021 The Author(s).
Références
Bioinformatics. 2011 Feb 1;27(3):431-2
pubmed: 21149340
J Clin Invest. 2017 Sep 1;127(9):3441-3461
pubmed: 28805663
Cell Cycle. 2009 May 15;8(10):1539-43
pubmed: 19395871
J Cell Physiol. 2018 Oct;233(10):6851-6865
pubmed: 29665093
Exp Ther Med. 2019 Oct;18(4):3062-3070
pubmed: 31555388
High Alt Med Biol. 2016 Dec;17(4):281-293
pubmed: 27500591
Int Rev Immunol. 2018 Mar 4;37(2):119-126
pubmed: 29231767
Nat Cell Biol. 2015 Jan;17(1):95-103
pubmed: 25438054
Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4215-4223
pubmed: 31618425
Exp Ther Med. 2015 Sep;10(3):915-920
pubmed: 26622414
Am J Cancer Res. 2018 Jul 01;8(7):1126-1141
pubmed: 30094089
Mol Genet Genomic Med. 2019 Mar;7(3):e542
pubmed: 30672138
Mol Nutr Food Res. 2019 Oct;63(19):e1801390
pubmed: 31338984
J Exp Med. 2017 Jun 5;214(6):1753-1767
pubmed: 28465464
Cancer Lett. 2015 Apr 28;360(1):76-86
pubmed: 25681036
Int Immunol. 2006 May;18(5):671-7
pubmed: 16569682
Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1217-28
pubmed: 10752963
J Clin Invest. 2014 Apr;124(4):1723-33
pubmed: 24569454
Med Sci Sports Exerc. 2002 Dec;34(12):1886-91
pubmed: 12471292
JAMA. 1981 Feb 13;245(6):581-6
pubmed: 7452886
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Am J Respir Crit Care Med. 2012 Jan 15;185(2):192-8
pubmed: 22071330
Clin Sci (Lond). 2012 Mar;122(6):299-309
pubmed: 21973220
Curr Top Microbiol Immunol. 2014;380:69-92
pubmed: 25004814
High Alt Med Biol. 2004 Summer;5(2):110-24
pubmed: 15265333
Front Immunol. 2017 May 30;8:628
pubmed: 28611780
Respirology. 2009 Jan;14(1):46-52
pubmed: 19144048
J Mol Med (Berl). 2016 Mar;94(3):277-86
pubmed: 26830628
Clin Rheumatol. 2013 Dec;32(12):1703-9
pubmed: 23934388
Medicine (Baltimore). 2017 Sep;96(39):e8222
pubmed: 28953687
Oncogene. 2003 Aug 7;22(32):5045-54
pubmed: 12902987
Circ Res. 2014 Sep 26;115(8):696-708
pubmed: 25085941
High Alt Med Biol. 2009 Spring;10(1):25-32
pubmed: 19326598
Physiol Rev. 2016 Oct;96(4):1297-325
pubmed: 27535639
Semin Ophthalmol. 2010 Jan-Mar;25(1-2):13-5
pubmed: 20507191
JAMA. 1976 Nov 8;236(19):2193-5
pubmed: 989810
PLoS One. 2013 May 16;8(5):e63548
pubmed: 23696831
PLoS One. 2010 Feb 01;5(2):e8898
pubmed: 20126538
High Alt Med Biol. 2001 Winter;2(4):539-44
pubmed: 11809095
J Anat. 2005 Apr;206(4):319-48
pubmed: 15817102
Microrna. 2015;4(3):158-67
pubmed: 26527285
Biosci Rep. 2018 Dec 18;38(6):
pubmed: 30487161
Eye (Lond). 2018 Feb;32(2):370-374
pubmed: 28912514
Ophthalmology. 1999 Oct;106(10):1924-6; discussion 1927
pubmed: 10519586
N Engl J Med. 2001 Jul 12;345(2):107-14
pubmed: 11450659
J Gene Med. 2016 Sep;18(9):244-9
pubmed: 27552709
Nucleic Acids Res. 2011 Jan;39(Database issue):D561-8
pubmed: 21045058
Int J Mol Med. 2017 Feb;39(2):287-296
pubmed: 28000848
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4300-8
pubmed: 26176867
Mol Cells. 2018 Apr 30;41(4):257-263
pubmed: 29665674
J Clin Invest. 2010 Nov;120(11):4141-54
pubmed: 20972335